# ELEPSIA XR
> **NDA204417** · New Drug Application · Sponsor: TRIPOINT · Approved 2018-12-20
## Drug
- **FDA Application Number:** NDA204417
- **Application type:** New Drug Application
- **Brand name:** ELEPSIA XR
- **Generic name:** LEVETIRACETAM
- **Active ingredients:** LEVETIRACETAM
- **Dosage form:** TABLET, EXTENDED RELEASE
- **Route:** ORAL
- **Marketing status:** Discontinued
- **Sponsor:** TRIPOINT
- **Manufacturer:** TRIPOINT THERAPEUTICS, LLC
- **First approval:** 2018-12-20
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204417)
---
*AI Analytics · CC0 1.0*